Oncimmune Ltd of Nottingham at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Manufacturers

Oncimmune Ltd

Clinical Sciences Building, City Hospital, Hucknall Road, NG5 1PB Nottingham
United Kingdom of Great Britain and Northern Ireland

This company is co-exhibitor of
Gambica Association Limited

Hall map

MEDICA 2019 hall map (Hall 1): stand F03-10

Fairground map

MEDICA 2019 fairground map: Hall 1

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Our products

Product category: Diagnostic tests for cancer

EarlyCDT® - Lung

A simple, affordable blood test for the early detection of lung cancer.

Lung is an extensively validated test for the levels of seven autoantibodies to tumour-associated antigens. It can detects all types of lung cancer at all stages of disease (I-IV) with high accuracy.

Extensively Studied and Validated

  • Over 25 peer-reviewed clinical publications
  • More than 60 peer-reviewed oral and poster presentations at key conferences
  • Clinically validated in seven independent cohorts and more than 120,000 patient samples, generating 12 million data points
  • Clinically audited in 1600 patients
  • Optimised for use in indeterminate pulmonary nodules
  • Meets all the American Thoracic Society criteria for clinical utility for biomarker test use to risk stratify pulmonary nodules
  • Over 155,000 commercial tests run in our CLIA-certified laboratory in Kansas, USA

More Less

Product category: Diagnostic tests for cancer

SeroTag® Platform

Oncimmune’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer.  As a result, SeroTag® is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

SeroTag® for autoimmune disease
The pathology of autoimmune diseases is intricate, and is characterised by a complex, maladaptive response of the immune system. This underlying process provides us with a window of opportunity, as autoantibodies are often produced early during the development of autoimmune diseases (sometimes even years before diagnosis), which can often provide insights into how a disease will manifest and progress. The advance warning signs given by autoantiantibodies makes them the biomarker of choice for autoimmune diseases.

To date, autoantibodies have not been analysed systematically in this field, and their potential to define the status of a patient’s immune-competence and responsiveness to treatment remains largely untapped.

Ocimmune is applying its SeroTag® platform to identify novel biomarkers, enabling patient subgrouping within autoimmune diseases—thereby supporting the successful development of therapies.

As a result of its SeroTag® work, Oncimmune has already developed the NavigAID range of stratification arrays for a number of indications, such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s Disease (SjS) and others.

In addition, SeroTag® has also been used for the development of a number of in vitro diagnostic products for multiple autoimmune indications, such as the Multilisa BICD2 panel for SSc. This forms part of Oncimmune’s unique cascade, from initial discovery through validation and commercialisation.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally-invasive liquid biopsies. SeroTag analyses autoantibodies—some of the most stable analytes—and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune’s NavigAID disease-specific stratification panels—precision medicine tools which are enabling patient and disease stratification and support therapeutic development.

 SeroTag® for immuno-oncology
The activity of autoantibodies in patients set to receive, or currently receiving, cancer immunotherapy offers a unique opportunity to support the development of safer, more effective immuno-oncology treatments.

Although the significance of autoantibodies in immuno-oncology is now being recognised, a systematic analysis has yet to be performed. Such autoantibody discovery and the immuno-profiling of patients holds great promise to address challenges such as cancer immunotherapy response prediction, as well as the prediction and monitoring of irAEs.

SeroTag® is currently being used to do exactly this. In line with our work in autoimmune diseases, SeroTag® enables the discovery and development of minimally-invasive liquid biopsy biomarkers, which is helping to expand Oncimmune’s NavigAID offering to support the development of immunotherapeutic anticancer drugs.

Through our partnerships and strategic collaborations with world-leading institutes such as the National Center for Tumor Diseases (NCT) in Germany, the National Cancer Institute (NCI) in the USA and Gustave Roussy (GR) in France, we have already successfully applied SeroTag® to a number of indications and immunotherapies and have been able to demonstrate that the platform is enabling the immuno-profiling of IO patients.

More Less

Product category: Diagnostic tests for cancer

NavigAID

NavigAID for Autoimmune Disease: Stratifying patients for improved therapeutic success
 
Autoimmune diseases are highly diverse, and the level of patient heterogeneity observed makes the development of effective treatments challenging. One solution is to stratify patients based on the specific characteristics of their individual autoimmune disease, including the detection of biomarkers that are central to the disease’s pathology—autoantibodies.

Developing tools to detect autoantibody signatures in patients suffering from autoimmune diseases will enable the immune-competence of a patient to be assessed, and their therapeutic responsiveness to be predicted.
 
The SeroTag® biomarker identification platform has allowed Oncimmune to do this, and to develop an array of disease-specific NavigAID stratification panels to profile individual patients’ diseases. This enables the stratification of patients into distinct disease subgroups based on their autoantibody profiles, an approach which is designed to help predict treatment response and support better patient management.

More Less

About us

Company details


Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT—Lung and EarlyCDT—Liver.

To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT—Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland.

Oncimmune is headquartered in Nottingham (UK) with a CLIA lab in Kansas (US) and offices in London (UK), Dortmund (Germany) and Shanghai (China).

Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

Oncimmune acquired the immuno-profiling company Protagen AG in March 2019.

More Less